Kaneka Corporation
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 6 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Major Holders
Updated 2026/01/11| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
972.8K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
680.6K | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
679.9K | +4.60% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
458.7K | +12.87% | |
|
Victory Portfolios-Victory Trivalent International Small-Cap Fund
|
326.8K | +0.93% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
257.5K | 0.00% |
Dividend History 2Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥150 | +30.4% |
| 2024 | ¥115 | +4.5% |
| 2023 | ¥110 | -4.3% |
| 2022 | ¥115 | +15.0% |
| 2021 | ¥100 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥691,530M | ¥755,821M | ¥762,302M | ¥807,200M |
| Gross Profit | ¥196,649M | ¥198,926M | ¥204,214M | ¥225,644M |
| Operating Income | ¥43,563M | ¥35,088M | ¥32,579M | ¥40,050M |
| Pretax Income | ¥37,469M | ¥34,338M | ¥40,169M | ¥40,796M |
| Net Income | ¥26,487M | ¥23,008M | ¥23,220M | ¥25,309M |
| EPS | ¥404.95 | ¥348.66 | ¥356.87 | ¥399.67 |
| Operating Margin | 6.30% | 4.64% | 4.27% | 4.96% |
| Balance Sheet | ||||
| Total Assets | ¥726,959M | ¥782,640M | ¥870,205M | ¥920,143M |
| Total Equity | ¥387,768M | ¥417,992M | ¥454,110M | ¥471,934M |
| Total Liabilities | ¥339,191M | ¥364,648M | ¥416,095M | ¥448,209M |
| Cash | ¥41,735M | ¥41,774M | ¥43,969M | ¥45,639M |
| Interest-bearing Debt | ¥132,829M | ¥175,943M | ¥195,095M | ¥223,058M |
| Equity Ratio | 53.34% | 53.41% | 52.18% | 51.29% |
| D/E Ratio | 0.34 | 0.42 | 0.43 | 0.47 |
| Cash Flow | ||||
| Operating CF | ¥34,106M | ¥28,710M | ¥61,911M | ¥41,252M |
| Investing CF | -¥39,595M | -¥41,970M | -¥58,771M | -¥55,038M |
| Financing CF | -¥1,105M | ¥12,352M | -¥1,519M | ¥14,453M |
| Free CF | -¥5,824M | -¥13,281M | -¥3,355M | -¥14,729M |
| Efficiency | ||||
| ROE | 6.83% | 5.50% | 5.11% | 5.36% |
| ROA | 3.64% | 2.94% | 2.67% | 2.75% |
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥4,717
Rating Score: 2.67 (Based on 6 analysts)
※1=Strong Buy, 5=Strong Sell
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire - Yahoo Finance ↗
Kaneka Corp: Quiet Chemical Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS ↗
Company Information
About
Kaneka Corporation engages in the manufacture and sale of polyvinyl chloride (PVC), crosslinked PVC, PVC-PVAc polymers, paste PVC, acryl grafted-vinyl chloride copolymer, and chlorinated PVC in Japan and internationally. It provides impact modifiers, processing aids, specialty additives, toughener for thermosetting resins, silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, and biodegradable polymer, as well as engineering resin for injection molding, acrylic film, and isobutylene-based thermoplastic elastomer products. The company also offers polypropylene and kanelite foams, extruded polystyrene foam insulation, polyimide film, transparent film for optical use, high thermal conductive graphite sheets, multi-layer insulation, transparent conductive film, and thermo-resistant, and light-resistant transparent resin products. In addition, it provides photovoltaic power generation systems for residences, public, and industrial installations; eco fur, flame-retardant, hair accessory, and new materials; and organic EL lighting panels, lithium-ion battery, and biosurfactant. Further, the company offers intervention, blood purification, gastroenterology intervention, testing equipment, regenerative medicine and cell therapy, and genetic diagnostic products; and low molecular pharmaceutical materials, affinity chromatography resin for purification of a monoclonal antibody, biopharmaceuticals, transdermal medicine, and innerwear with shock-absorbing pad. Additionally, it provides dairy products, yogurt, margarine, fat and oils, whipping cream, filling, baker's yeast/ dough improver, processed fruits, butter, shortening, cacao butter alternatives, cream for kneading and other uses, frozen dough, spices, antifreeze materials; and pharma and supplemental nutrition solutions, which include coenzyme, probiotics, and dietary ingredients, as well as fertilizers. The company was incorporated in 1949 and is headquartered in Tokyo, Japan.